================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

          (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 150(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                FOR THE QUARTERLY PERIOD ENDING: AUGUST 31, 2007

          ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

              For the transition period from _________ to _________

                           COMMISSION FILE NO. 1-11047

                           SPARTA SURGICAL CORPORATION
           (Name of Small Business Issuer as specified in its Charter)


                  Delaware                                  22-2870438
            (State Incorporated)                   (I.R.S. Employer ID Number)

5445 DTC Parkway, Suite 520
Greenwood Village, CO                                        80111
(Address of Principal Executive Offices)                   (Zip Code)

                                  848-391-2893
                           (Issuer's Telephone Number)

Check whether the issuer (I) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days: Yes (X) No ( ).

           Securities registered pursuant to Section 12(b) of the Act:

                                                       Name of each exchange on
Title of Class                                             which registered

$0.002 Par Value Common Stock                                    None.
$4.00 Par Value Redeemable Convertible
  Preferred Stock                                                None.
$4.00 Par Value Series A Convertible
  Preferred Stock                                                None.





<PAGE>

           Securities registered pursuant to Section 12 (g) of the Act

                          $0.002 Par Value Common Stock
              $4.00 Par Value Series A Convertible Preferred Stock
               $4.00 Par Value Series Convertible Preferred Stock

The Registrant had $4,565 in revenue for its most recent fiscal year.

As of August 31, 2007, 9,973,830 shares of Registrant's Common Stock, 82,533
shares of Redeemable Convertible Preferred Stock, and 27,818 shares of Series A
Convertible Preferred Stock were outstanding.




















<PAGE>

                           SPARTA SURGICAL CORPORATION

                                   Form 10-QSB

                                      INDEX
Part I.  Financial Information

         Item 1.  Financial Statements (Unaudited)                           1

                  Balance Sheet
                  As of August 31, 2007
                  (Unaudited)                                                1

                  Statements of Operations
                  for the Three and Six Months Ended
                  August 31, 2007 and 2006
                  (Unaudited)                                                2

                  Statements of Cash Flows
                  for the Six Months Ended
                  August 31, 2007 and 2006
                  (Unaudited)                                                3

         Item 2.  Management's Discussion and
                  Analysis of Financial Condition
                  and Results of Operations
                  (Unaudited)
                                                                            11
         Item 3.  Controls and Procedures
                                                                            15
Part II. Other Information and Change in Securities

         Item 1.  Legal Proceedings                                         15

         Item 2.  Change in Securities                                      15

         Item 3.  Default upon Senior Securities                            15

         Item 4.  Submission of Matters to Vote of Security Holders         15

         Item 5.  Other Information                                         15

         Item 6.  Exhibits and Signatures                                   16





<PAGE>
                           Sparta Surgical Corporation
                                  Balance Sheet
                                 August 31, 2007
                                   (unaudited)

ASSETS
         Accounts Receivable                                      $      11,343
                                                                  --------------

            TOTAL ASSESTS                                         $      11,343
                                                                  ==============



LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
         Accounts Payable                                         $      82,752
         Accrued Taxes Payable                                           95,512
         Accrued Interest for Notes Payable                              98,848
         Notes Payable to Trust                                         198,718
         Notes Payable to Trust                                         181,568
         Notes Payable to Credit Facility                                52,072
         Dividend Payable on Preferred Stock                            145,224
                                                                  --------------

            TOTAL CURRENT LIABILITIES                                   854,694
                                                                  --------------


STOCKHOLDERS' EQUITY Preferred Stock:
         1992 Non-cumulative Convertible Redeemable
           Preferred Stock, 165,000 shares authorized,
           82,533 shares issued and outstanding.                        330,132
         Series A Cumulative Convertible Preferred
           Stock, 30,000 shares authorized, 27,818
           shares issued and outstanding.                               111,272
            Series AA Cumulative Convertible Preferred
           Stock, 875,000 Shares authorized, none issued
           and outstanding.                                                   -
         Common Stock, $0.002 par value, 25,000,000
           authorized and 9,973,830 outstanding                          15,467
         Additional Paid in Capital                                  14,486,197
         Accumulated Deficit                                        (15,786,419)
                                                                  --------------


            TOTAL STOCKHOLDERS' EQUITY                                 (843,351)
                                                                  --------------

            TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY            $      11,343
                                                                  ==============






                 See accompanying notes to financial statements



                                       1
<PAGE>

                           Sparta Surgical Corporation
                            Statements of Operations
                                   (unaudited)


                                        For the Three          For the Six
                                        Months Ended:          Months Ended:
                                     August 31, August 31, August 31, August 31,
                                       2007        2006      2007        2006


Revenue                              $   1,436  $       -  $   4,565  $       -
                                     -------------------------------------------

Gross Profit                             1,436          -      4,565          -
                                     -------------------------------------------

Selling, General and
Administrative Expenses                  2,120     87,569     10,803     91,053
                                     -------------------------------------------

Loss from Operations                      (684)   (87,569)    (6,238)   (91,053)
                                     -------------------------------------------

Other Income (Expense):
     Interest Expense                   (6,954)    (5,660)   (13,908)   (11,337)
                                     -------------------------------------------

     Total Other Income (Expense)       (6,954)    (5,660)   (13,908)   (11,337)
                                     -------------------------------------------

     Net Loss                           (7,638)   (93,229)   (20,146)  (102,390)

Cumulative Preferred Dividends          (9,999)    (4,656)   (19,998)    (9,312)
                                     -------------------------------------------

     Net Loss to Common Shareholders $ (17,637) $ (97,885) $ (40,144) $(111,702)
                                     ===========================================

     Weighted Average Shares         9,973,830  9,973,830  9,973,830  9,973,830
                                     ===========================================

Basic and Diluted Earning per Share
     Net Loss per share              $    0.00  $    0.01  $    0.00  $    0.01
                                     ===========================================



See accompanying notes to financial statement



                                       2
<PAGE>

Sparta Surgical Corporation
Statements of Cash Flows
           (unaudited)



                                                     For the Six Months Ended:

                                                    August 31,      August 31,
                                                       2007           2006

Cash flows from operating activities
Net Loss                                          $     (40,144)       (111,702)
                                                  ------------------------------
Adjustments to reconcile operating loss
  to net cash used in operating activities:
         Preferred dividends                             19,998               -
       Change in operating assets and liabilities:
           Accounts receivable                           (4,565)              -
           Accounts payable                               7,240               -
           Accrued expenses                              13,908         111,702
                                                  ------------------------------

         Net cash used in operating activities           (3,563)              -
                                                  ------------------------------

Cash flows from financing activities
         Proceeds from note payable                       3,563               -
                                                  ------------------------------
Net cash provided by financing activities                 3,563               -
                                                  ------------------------------

Net change in cash and cash equivalents                       -               -

Cash and cash equivalents at
     beginning of period                                      -               -
                                                  ------------------------------

Cash and cash equivalent at
     end of period                                $           -   $           -
                                                  ==============================


See accompanying notes to financial statements




                                       3
<PAGE>

Sparta Surgical Corporation

                        Notes to the Financial Statement

Note 1. Business and Summary of Significant Accounting Policies

Sparta Surgical Corporation, (the "Company"), a non-operating public company
since May 2002, was incorporated in Delaware on March 23, 1984. The Company was
engaged in the research, development, manufacturing and marketing of surgical
and electrotherapy products for the worldwide healthcare industry. In May 2002,
the Company divested substantially all of its assets and ceased operations. As a
result, the Company retained no assets after ceasing operations, and has
performed only administrative duties as a transitory, or shell, corporation.
Since May 2002, the Company has sought to acquire a new business opportunity. In
October 2006, the Company was appointed as an exclusive independent sales
representative to market certain surgical instruments and disposable devices and
thereby re-entered the medical device industry. In addition, the Company's
affiliate was appointed to market exclusively certain electrotherapy devices and
accessories. Accordingly, the Company and its affiliate intends to utilize this
new relationship to form a basis for its future activities and attempt to
produce income. However, there can be no assurance that the Company and its
affiliate will succeed with this new business strategy and or produce any future
income.

In June 2002 and March 2004, the Company issued to LKDTBJP Living Trust, (the
"Living Trust"), various Convertible Secured Promissory Notes, (the "Convertible
Notes") in the amount of $380,286 for assuming certain of the Company's debt and
notes payable. The Convertible Notes, both principal and accrued interest, were
due on June 15, 2006 and May 17, 2006, at 6% interest per annum. On May 12,
2006, Living Trust agreed to extend payments on both principal and accrued
interest under the Convertible Notes until February 28, 2008. At the option of
the Living Trust, the Convertible Notes are convertible at any time into
15,000,000 shares of the Company's Common Stock.

In September 2005, the Company entered into a Revolving Credit Facility
Agreement (the "Agreement"), by and between Gary A. Agron (the "Agron") and
Living Trust (collectively the "Lender"). This Agreement allows the Company to
borrow up to $100,000 with interest charged at 6.0% per annum, and both
principal and accrued interest is due on February 28, 2008. The Company further
agreed not to issue any additional equity or any other type of security without
the written consent of the Lender. In consideration of the Lender providing a
revolving credit, the Company has agreed to issue each of Agron and Living Trust
46,269,023 shares for a total of 92,538,046 shares of the Company's Common Stock
(the "Loan Shares") valued at $9,254. On October 6, 2006, subject to the
confirmation of the Company's Plan of Reorganization and Accompanying Disclosure
Statements, the number of shares will be reduce to 10,000,000 valued at $1,000.



                                       4
<PAGE>

The Company further acknowledged that it currently does not have sufficient
shares of common stock authorized for the issuance of the Loan Shares, however,
the Company shall take all reasonable actions necessary, including the holding
of a shareholder meeting to amend the Company's Certificate of Incorporation to
authorize shares of the Company's common stock so that Loan Shares may be
issued.

In September 2005, the Company did not have sufficient funds to pay Allan J.
Korn, its President, for his past services. Therefore the Company authorized
issuance of 5,443,415 shares of its Common Stock valued at $544.34 to Mr. Korn,
who has acted as the Company's sole officer and director without compensation
for the past four years. On October 6, 2006, subject to the confirmation of the
Company's Plan of Reorganization,and Accompanying Disclosure Statements, the
Company and Mr. Korn agreed to reduce the number of shares to 50,000. In
November 2006, the Company's affiliate did not have sufficient funds to pay Mr.
Korn for assuming the position of President, sole officer and director.
Therefore, the affiliate agreed to authorize to issue 25,000 shares of its
Common Stock to Mr. Korn.

In November 2006, the Company's affiliate entered into a $100,000 Revolving
Credit Facility Agreement by and between the Lender. The terms and conditions
under this Credit Facility are the same as the Company's with the exception that
in consideration of the Lender providing the credit facility, the affiliate
authorized to issue 850,000 shares of its common stock to the Lender. These
shares are valued at approximately $85.

Significant Accounting Policies

There have been no significant changes in Company's significant accounting
policies during the six months ended August 31, 2007 as compared to what was
previously disclosed.

Income Taxes

No provision for federal and state income taxes has been recorded as the Company
has incurred net operating losses through August 31, 2007. The Company believes
sufficient uncertainty exists regarding the realizability of the deferred tax
assets such that a full valuation allowance is required, leaving a net deferred
tax asset of $-0-. The Company also has net operating loss carryforwards for tax
reporting periods. The Company retained no assets after ceasing operations on
May 2, 2002, and has performed only administrative duties as a transitory, or
shell, corporation. On November 2006, the Company re-entered the medical device
industry by being appointed as the exclusive independent sales representative
for certain surgical instruments and disposable devices.



                                       5
<PAGE>

Basic and Diluted Earnings Per Common Shares

In accordance with Financial Accounting Standards Boards ("FASB") No. 128, basic
earnings per share is computed by dividing net income by the number of weighted
average common shares outstanding during the year. Diluted earnings per share is
computed by dividing net income by the number of weighted average common shares
outstanding during the year. For the three and six months ended August 31, 2007
and 2006 there is no difference between the basic and diluted loss per share, as
there were no dilutive stock options.

                                        For the Three          For the Six
                                        Months Ended:          Months Ended:
                                     August 31, August 31, August 31, August 31,
                                       2007        2006      2007        2006




Numerator:
Net Loss applicable
to common stockholders               $ (17,637) $ (97,885) $ (40,144) $(111,702)

Denominator
Weighted average
shares outstanding
during the period                    9,973,830  9,973,830  9,973,830  9,973,830

Basic and diluted
loss per common
share                                $   (0.00) $   (0.01) $   (0.00) $   (0.01)

Revenue Recognition

The Company recognizes revenue when commissions are earned under the Exclusive
Sales Representative Agreement. Provision for allowances, and other adjustments
are provided for in the same period the related revenues are recorded.

Long-Lived Assets

The Company  reviews its  long-lived  assets for impairment  whenever  events or
changes in circumstances  indicate that the carrying amount of the asset may not
be recovered.  The Company looks primarily to the undiscounted future cash flows
in its assessment of whether or not long-lived assets have been impaired.

Recently Issued Accounting Pronouncements

In September 2006, the Securities and Exchange Commission ("SEC") released Staff
Accounting Bulletin No. 108, "Considering the Effects of Prior Year
Misstatements when Quantifying Misstatements in Current Year Financial
Statements," ("SAB No. 108"). SAB No. 108, which is effective for fiscal years
ending after November 15, 2006, provides guidance on how the effects of prior
year uncorrected misstatements, previously deemed to be immaterial, must be
considered and adjusted during the current year. The Company does not anticipate
that the adoption of SAB 108 will have a material effect on its statements of
operations in future periods.




                                       6
<PAGE>

Use of Estimates

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America require management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosures of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expense during the
reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The fair value of accounts payable and accrued expenses approximates carrying
value due to the short-term nature of such instruments. The fair value of debt
obligations with related parties and individuals is not determinable due to the
terms of the debt and there is no comparable market for such debt.

Concentration of Credit Risk

There are no financial statements that potentially subject the Company to
significant concentrations of credit risk.

Note 2 - Going Concern

The accompanying financial statements have been prepared on a going concern
basis which contemplates the realization of assets and liquidation of
liabilities in the ordinary course of business.

During 2001 and 2002, the Company entered into and completed an agreement to
sell all of its operating assets.

In September 2005, the Company entered into a Revolving Credit Facility. This
Revolving Credit Facility allows the Company to borrow up to $100,000 with
interest charged at 6.0% per annum.




                                       7
<PAGE>

In November 2006, the Company and its affiliate filed for protection under
Chapter 11 in the United States of Bankruptcy Court for the District of
Colorado.


Note 3- Related Party Transactions

Office Space

The Company's uses office space located in its Chief Executive Officer's office.
The Company estimates the fair value of these services to be $1,200 per year and
these amounts have not been recorded in the financial statements.

Amounts Due to Related Parties

As of August 31, 2007, the Company had amounts due to the Lender in the amount
of $52,072 in connection with the $100,000 Revolving Credit Facility Agreement
dated September 9, 2005.

As of August 31, 2007, in connection with the Company's Convertible Notes, the
Company had amounts due of $380,286, including accrued interest of $98,848, in
the aggregate amount of $$479,134 to Living Trust.

Current Notes payable consists of the following:

Credit Facility dated September 9, 2005 for
$100,000 at 6% due February, 2008                                 $      52,072

6% note due in February 2008, collateralized
by substantially all assets of the Company
and convertible into 7,500,000 shares of the
Company's Common Stock, $0.002 par value.                               198,718

6% note due in February 2008, collateralized
by substantially all assets of the Company
and convertible into 7,500,000 shares of the
Company's Common Stock, $0.002 par value.                               181,568
                                                                  --------------

                                                                  $     432,358
                                                                  ==============


                                       8
<PAGE>

Note 4 - Stockholders' Equity

Preferred Stock

The authorized Preferred Stock of the Company consists of 2,000,000 shares,
$4.00 par value. The Preferred Stock may be issued in series from time to time
with such designations, rights, preferences, and limitations as the Board of
Directors of the Company may determine by resolution. The rights, preferences
and limitations of separate series of Preferred Stock may differ with respect to
such matters as may be determined by the Board of Directors, including without
limitation, the rate of dividends, method and nature of payment of dividends,
terms of redemption, amounts payable on liquidation, sinking fund provisions,
conversion rights and voting rights.

1992 Preferred Stock

The Company has authorized 165,000 shares of Non-Cumulative Convertible
Preferred Stock (the "1992 Preferred Stock"). The holders of the 1992 Preferred
Stock shall be entitled to receive non-cumulative dividends, at the rate of 10%
per annum or $0.40 per share, for each year that the Company has net income
after taxes. The holders of 1992 Preferred Stock are entitled to vote on matters
upon which holders of the common stock have the right to vote, and shall be
entitled to the number of votes equal to the number of full shares of common
stock into which the shares of 1992 Preferred Stock could be converted. Each
share of 1992 Preferred Stock is convertible at the option of the holder into
one third of one share of common stock. Each preferred share is subject to
redemption at the Company's option at $4.00 per share under certain conditions.
The liquidation preference for the 1992 Preferred Stock is $4.00 per share.

Series A Preferred Stock

The Company has authorized 30,000 shares of Series A Convertible Redeemable
Preferred Stock (the "Series A Preferred Stock"). The holders of the Series A
Preferred Stock receive cumulative dividends at the quarterly rate of $0.375 per
share. The holders of Series A Preferred Stock have no voting rights except as
to matters affecting the rights of preferred stockholders or as required by law.
In connection with any such vote, each outstanding share of Series A Preferred
Stock has one vote. The Series A Preferred Stock is redeemable at the Company's
option, for cash at $10.00 per share plus any accrued and unpaid dividends. The
Series A Preferred Stock is $10.00 per share. The 1992 preferred Stock carries
liquidation rights senior to the Series A Preferred Stock.





                                       9
<PAGE>

Series AA Preferred Stock

The Company has authorized 875,000 shares of Series AA Convertible Redeemable
Preferred Stock (the "Series AA Preferred Stock"). The holders of the Series AA
Preferred Stock receive cumulative dividends at the annual rate of $0.28 per
share, payable semi-annually. The holders of the Series AA Preferred Stock have
no voting rights except as to matters affecting the rights of preferred
stockholders or as required by law. In connection with any such vote, each
outstanding share of Series AA Preferred Stock has one vote. The Series AA
Preferred Stock was convertible at any time through February 10, 2001 into
shares of common stock at a rate of 9 shares of common stock for each two shares
of Series AA Preferred Stock. The Series AA Preferred Stock will automatically
be converted into common stock at this rate in the event that the daily average
bid and ask price of common stock average $3.00 per share or more over a thirty
consecutive day period through February 10, 2001. At any time subsequent to
February 10, 2001, each two shares of Series AA Preferred Stock are redeemable
at the Company's option, for cash at $10.00 or $8.00 plus any accrued and unpaid
dividends in the event that the daily average bid and ask price of the common
stock average at least $2.00 per share or $3.00 per share, respectively, over a
thirty consecutive day period. The liquidation preference for the Series AA
Preferred Stock is $4.00 per share. The 1992 Preferred Stock and Series A
Preferred Stock carry liquidation rights senior to the Series AA Preferred
Stock.

As of August 31, 2007, the Company has accrued $145,224 for cumulative preferred
dividends.

Note 5 - Stock Options and Warrants

The 1987 Stock Option Plan (the "Plan") provided for the grant of both incentive
stock options and non-qualified stock options. A total of 250,000 shares of
common stock have been reserved for issuance under the Plan. In April 2000, the
Company extended the 1987 Stock Option Plan for an additional ten-year period,
until October 1, 2007. The Plan expired on October 1, 2007. As of November 30,
2007, there are no outstanding Option and Warrants issued.




                                       10
<PAGE>

Item 2.
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS

We are a non-operating public company with no current revenues as we divested
substantially all of our assets and ceased operations in May 2002. In recent
years we have experienced losses from operations and continue to suffer from a
deficiency in available working capital. Except for the historical information
contained herein the matters set forth in this report are forward-looking
statements within the meaning of "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to differ
materially. These risks are detailed from time to time in our periodic reports
filed with the Securities and Exchange Commission, including our Annual Report
on Form 10- KSB, Quarterly Reports on Form 10-QSB and other periodic filings.
These forward-looking statements speak only as of the date hereof. We disclaim
any intent or obligation to update these forward-looking statements.

These statements relate to future events in future financial performance and
involve known and unknown risks, uncertainties and other factor's that may cause
our or our industry's actual results, performance or achievements to be
materially different from these expressed or implied by any forward-looking
statements. All of these matters are difficult or impossible to predict
accurately and may be beyond our control. Although we believe that the
assumptions underlying our forward-looking statements are reasonable, any of the
assumptions could be inaccurate, therefore, there can be no assurance that the
forward-looking statements included in this Form 10-QSB will prove to be
accurate. The following discussions should be read in conjunction with the
unaudited Financial Statements and notes thereto, appearing elsewhere herein.

Risk Factors Affecting Future Operating Results

The following important factors, among others, could cause actual results to
differ materially from those contained in the forward-looking statements in this
Form 10-QSB, or presented elsewhere by management from time to time. We wish to
caution stockholders and investors that the following important factors, among
others, in some cases have affected, and in the future could affect our actual
results and could cause our actual results to differ materially, from those
expressed in any forward-looking statements made by us. These statements under
this caption are intended to serve as cautionary statements within the scope of
the Private Securities Litigation Reform Act of 1995. The following information
is not intended to limit in any way the characterization of other statements or
information under other caption as cautionary statements for such purpose. These
factors could have a material adverse effect on our non-operating business,
operating results and financial condition. Our results of operations vary
significantly from year to year and from quarter to quarter. We have incurred
net losses in prior years and can't assure future profitability. At August 31,
2007, our accumulated deficit was approximately $15,786,419.



                                       11
<PAGE>

The following are important factors that could cause actual results to differ
materially from those anticipated in any forward-looking statements made by or
on behalf of us.

We have incurred significant operating losses and will not be profitable in the
future as the Company has experienced circumstances which raise substantial
doubt about its ability to continue as a going concern.

We have discontinued all of our operations since May 2002, as we divested
substantially of our operating assets. We have incurred approximately
$15,786,419 in cumulative net losses from inception.

There is no significant trading market for our common stock.

Our common stock is not eligible for trading on any national or regional
exchange as we were delisted from the OTC Bulletin Board on July 2001. Our
common stock has no trading activity on the non NASDAQ Other OTC (Pink Sheet
unqualified) pursuant to Rule 15c2- 1 1 of the Securities Exchange Act of 1934.

Because our common stock is classified as "penny stock", trading is limited and
the common stock price declined to virtually no value and therefore is very
difficult to sell.

Because our common stock falls under the definition of "penny stock", the
trading in our common stock is limited because broker-dealers are required to
provide their customers with disclosure documents prior to allowing them to
participate in transactions involving our common stock.

We do not anticipate paying dividends.

We have not paid any cash dividend on our common stock since our inception and
we do not anticipate paying cash dividends in the foreseeable future and since
2001 we have not paid any dividends to the holders of the Company's preferred
stocks.

One of our current stockholders has significant influence over our management
and directors and may take actions that may not be in the best interest of other
stockholders.

Our co-founder beneficially owns approximately 66% of our common stock.
Therefore, he will be able, among other things, to elect directors.

We filed Chapter 11.

We filed for bankruptcy protection under Chapter 11 in the United States
Bankruptcy Court for the District of Colorado.


                                       12
<PAGE>

Results of Operations

Three Months Ended August 31, 2007 as Compared to Three Months Ended August 31,
2006.

We had $1,436 in revenues for the Three Months Ended August 31, 2007 ("Second
Quarter Ended Fiscal 2008") and no revenues for the Three Months Ended August
31, 2007 ("Second Quarter Ended Fiscal 2007") due to the Company divesting
substantially all of its assets and as a result ceasing operations on May 2,
2002. The increase in revenues is attributed to the Company generating sales
commissions relating to its appointment of being an exclusive independent sales
representative for a certain medical and disposable product line.

Selling, general and administrative ("SG&A") expenses for the Second Quarter
Ended Fiscal 2008 were $2,120, a decrease of $85,449 as compared to $87,569 in
expenses for the Second Quarter Ended Fiscal 2007. The decrease in SG&A expenses
for the Second Quarter Ended Fiscal 2008 is attributed to a one-time settlement
charge plus accrued interest and other related administrative expenses recorded
in Fiscal 2007.

Total Other Expenses for the Second Quarter Ended Fiscal 2008 were $6,954, an
increase of $1,294 as compared to $5,660 for Second Quarter Ended Fiscal 2007.
The Total Other Expense increase is attributed to additional interest expenses
relating to Notes Payables and Credit Facility and other administrative
expenses.

As a result of the foregoing, the net loss for the Second Quarter Ended Fiscal
2008 was $17,637, a decrease of $80,248 as compared to the net loss of $97,885
for the Second Quarter Ended Fiscal 2007. The decrease in the net loss for the
Second Quarter Ended Fiscal 2008 as compared to 2007 is attributed to the
one-time settlement charge as discussed above.

Six Months Ended August 31, 2007 as Compared to Six Months Ended August 31,
2006.

We had $4,565 in revenues for the Six Months Ended August 31, 2007 and no
revenues for the Six Months Ended August 31, 2006 due to the Company divesting
substantially all of its assets and as a result ceasing operations on May 2,
2002. The increase in revenues is attributed to the Company generating sales
commissions relating to its appointment of being an exclusive independent sales
representative for a certain medical product line.

Selling, general and administrative ("SG&A") expenses for the Six Months Ended
August 31, 2007 were $10,803, a decrease of $80,250 as compared to $91,053 in
expenses for the Six Months Ended August 31, 2006. The decrease in SG&A expenses
for the Six Months Ended August 31, 2007 is attributed to the one-time
settlement charge as discussed above.


                                       13
<PAGE>

Total Other Expenses for the Six Months Ended August 31, 2007 were $13,908, an
increase of $2,571 as compared to $11,337 for Six Months Ended August 31, 2006.
The Total Other Expense increase is attributed to additional interest expenses
relating to Notes Payables and Credit Facility and other administrative
expenses.

As a result of the foregoing, the net loss for the Six Months Ended August 31,
2007 was $20,146, a decrease of $91,556 as compared to the net loss of $111,702
for the Six Months Ended August 31, 2006. The decrease in the net loss for the
First Half of Fiscal 2008 as compared to 2007 is attributed to the one-time
settlement charge and administrative expenses as discussed above.

Liquidity and Capital Resources

Since inception, we have been undercapitalized and have experienced financial
difficulties. Our primary sources of working capital have been revenues from
operations, bank and private party loans and proceeds from the sale of
securities. Many of the bank and private party loans and certain of our other
obligations have required personal guarantees in order to continue to operate
our business. In May 2002, the Company divested substantially all of its assets
and ceased operations, and has performed only administrative duties as a
transitory, or shell, corporation. On October 2007, the Company re-entered the
medical device industry by being appointed as an exclusive independent sales
representative for certain surgical instruments and disposable devices. As of
November 30, 2007, the Company continued to generate revenues from the earned
sales commission. Our working capital at August 31, 2007 was negative in
deficit.

On June 15, 2002, and March 2004, we issued various convertible secured
promissory notes (the "Notes") to LKDTBJP Living Trust, (the "Living Trust") in
the aggregate amount of $380,286 for assuming certain of our trade and notes
payable. The terms of the Notes are that both of the principal and accrued
interest are due on February 28, 2008. The Notes carry a 6% interest per annum.
The Notes are convertible at any time into 15,000,000 shares of the Company's
common stock at the option of the Living Trust.. The value of these shares is
approximately $1,500.

In September 5, 2005, the Company entered into a Revolving Credit Facility
Agreement (the"Agreement"), by and between Gary A Agron and LKDTBJP Living
Trust, (collectively (the "Lender"). This Agreement allows the Company to borrow
up to $100,000 with interest charged at 6.0% per annum, and both principal and
accrued interest is due on February 28, 2008. The Company further agreed not to
issue any additional equity or any other type of security without the written
consent of the Lender. In consideration of the Lender providing this Agreement,
the Company has agreed to issue each of Agron and LKDTBJP Living Trust
46,269,023 shares of its Common Stock valued at $9,254. On October 6, 2006,
subject to the confirmation of the Company's Plan of Reorganization, and
Accompanying Disclosure Statements, the number of shares issued will be reduced
to 10,000,000 valued at $1,000.



                                       14
<PAGE>

Item 3. Controls and Procedures

The Company maintains controls and procedures designed to ensure that the
information required to be disclosed in the reports that the Company files or
submits under the Securities Exchange Act of 1934, is recorded, processed,
summarized and reported within the time periods specified in the rules and forms
of the Securities Exchange Commission. Based upon their evaluation of those
controls and procedures performed within 90 days of the filing date of this
report, the Company's chief executive officer and the principal financial
officer (or persons performing similar functions) concluded that the Company's
disclosure controls and procedures were adequate.

As a result of its evaluation, the Company has been made no significant changes
in its internal controls or other factors that could significantly affect the
controls and other procedures already in place.

Part II. Other Information

Item 1. Legal Proceedings.

On November 6, 2006, the Company filed its Voluntary Petition under Chapter 11
of the Title 1 of the United States Code Bankruptcy for District of Colorado
under Case#06-18117-ABC. On this petition date, the Company its Proposed Plan of
Reorganization and accompanying Disclosure Statement (the"Plan"). As of
November 12, 2007 , the United States Bankruptcy Court for the District of
Colorado has not yet ruled on the confirmation of the Plan.

Item 2. Changes in Securities

None.

Item 3. Default Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information

None.



                                       15
<PAGE>

Item 6. Exhibits and Reports on Form 8-K

a) Exhibits

Number            Description
------            -----------

31.1         Certification by Chief Executive and Chief Financial Officer
             pursuant to Sarbanes-Oxley Section 302.

32.1         Certification by Chief Executive and Chief Financial Officer
             pursuant to 18 U.S.C. Section 1350.

b) Reports on Form 8K
None



SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Sparta Surgical Corporation
        (Registrant)
Date: November 12, 2007                          By: /s/ Allan J. Korn
                                                    ---------------------
                                                 Allan J. Korn
                                                 Chief Executive Officer and
                                                 Chief Financial Officer
















                                       16

--------------------------------------------------------------------------------